Agilent to Acquire Dako for $2.2 Billion Acquisition is Next Step in Agilent’s Growing Role in Clinical Diagnostics Dako is one of the leading global providers of cancer diagnostics tools.

Kansept’s Dako could be just the tonic for knife nerds who yearn to really dial in the snap of their blade’s action.

With the launch of the Agilent Dako Omnis family, Agilent transitions beyond a one-size-fits-all model to offer a tailored portfolio—empowering labs to select the configuration that best meets ...

The deal makes sense, Bloomberg quotes Cowen & Co. analyst Doug Schenkel as saying, because "Dako is considered an attractive asset in tissue diagnostics, a market with robust underlying ...

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration (FDA) appr ...

Dako said the expanded “multi-year” collaboration will allow both companies to benefit from knowledge-sharing within drug-diagnostic R&D, particularly in relation to companion diagnostic products.

Dako, an Agilent Technologies (A) subsidiary, entered into an agreement with Merck & Co. Inc. (MRK) to develop companion diagnostic test for detecting cancer susceptibility among people.

Dako has been introducing high-quality antibodies for nearly 50 years, and the company still continues to expand knowledge within the field. Dako published the update to help drive further scientific ...